APAnna Placzek

Anna Placzek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Placzek has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Estimating the Economic Value of Supported Online Parent-Led Cognitive Behavioral Therapy to Prevent Child Anxiety Problems: Economic Evaluation of the MYCATS Cluster Randomized Controlled Trial

    by Shuye Yu, Tessa Reardon, Obioha C Ukoumunne, Rebecca Njuguna, Helen Dodd, Gemma Halliday, Clare Hill, Bec Jasper, Benjamin Jones, Peter J. Lawrence, et al.

    Background: Childhood anxiety disorders are common and lead to substantial negative long-term outcomes in various life domains. Although digital interventions for preventing childhood anxiety problems have been increasingly used in the recent decade, there is limited evidence documenting their cost-effectiveness (CE). Objective: This study aimed to evaluate the CE of a parent-led online cognitive behavioral therapy with therapist support (OSI+TS) alongside usual school practice (USP), compared to USP alone for children aged 4‐7 years at risk of anxiety disorders identified through universal school screening. Methods: The economic evaluation was conducted alongside the MYCATS trial (N=865), a parallel group, superiority cluster randomized trial across 95 primary or infant schools in England. Schools were randomized (1:1) to OSI+TS or USP, stratified by school-level deprivation. The primary analyses, at 12 months after randomization, considered child quality-adjusted life years (QALYs) as the health economic outcome, using both the UK adult and the Australia adolescent value sets, and costs were from the National Health Service and Personal Social Services perspective. Incremental cost-effectiveness ratios (ICERs) were compared to the UK National Institute for Health and Care Excellence (NICE) recommended threshold of £20,000-£30,000 (£1=US $1.35 as of September 10, 2026) per QALY gained, as per predefined Health Economics Analysis Plan. Sensitivity analyses included a societal perspective and the application of the new NICE cost-effectiveness threshold. Results: Children receiving OSI+TS gained 0.021 (95% CI 0.010-0.033; P <.001) and 0.043 (95% CI 0.021-0.064; P <.001) QALYs, respectively, for United Kingdom and Australia value sets, with an additional cost of £244.16 compared to school usual practice only, resulting in ICERs of £11,462.47 and £5,700.98, respectively. At the £20,000 threshold, OSI+TS had an 88.2% or 99.3% chance of being cost-effective. Conclusions: OSI+TS is cost-effective compared to usual school provision, supporting its future implementation for children at risk of anxiety problems.

  • Open Access

    Parent‐led CBT delivered via online and telephone support alongside usual school practice versus usual school practice only for young children identified as at risk for anxiety disorders through screening in schools: a cluster randomised controlled trial

    by Tessa Reardon, Obioha C. Ukoumunne, Helen Dodd, Gemma Halliday, Claire Hill, Bec Jasper, Benjamin Jones, Peter J. Lawrence, Fran Morgan, Anna Placzek, et al.

    Background: Providing accessible CBT for young children identified as at risk for anxiety disorders through screening in schools could reduce later problems. This study aimed to evaluate the effectiveness of parent‐led CBT delivered via online and telephone call support alongside usual school provision, compared to usual school provision only for young children identified through screening as having at least one risk. Methods: We conducted a pragmatic, parallel group, superiority cluster randomised controlled trial in 95 primary/infant schools in England. Parents of children (aged 4–7) in sampled classes completed screening, and children who screened positive for one or more risks (anxiety symptoms/inhibition/parent anxiety) were eligible for the trial. Schools (clusters) were randomised (1:1) to intervention or usual school practice, stratified by school‐level deprivation. Schools in both arms continued with usual provision, and parents in intervention schools were offered parent‐led CBT via online and telephone support. The primary outcome was the presence of an anxiety disorder diagnosis at 12 months, assessed via the ADIS‐P administered by independent assessors. Secondary clinical outcomes included parent‐reported child anxiety symptoms, related interference, externalising symptoms, additional risks and intervention targets at 12 weeks and 12 months. Primary analyses were conducted on the full intention‐to‐treat population. The trial was prospectively registered with ISRCTN 82398107. Results: In total, 2,328 children were screened; 1,172 were eligible; 865 enrolled. Forty‐eight schools (434 children) were assigned to intervention and 47 schools (431 children) to usual school practice. At 12 months, the overall frequency of anxiety disorders was low, 6.8% (21/310) of children in the intervention arm compared to 11.5% (36/312) in the usual school practice arm; this difference was not statistically significant (adjusted odds ratio 0.67 [0.37 to 1.21], p = .19). However, the intervention was superior to usual school practice across all secondary outcomes (standardised mean difference: 0.15 to 0.47 at 12 weeks; 0.19 to 0.41 at 12 months). No serious adverse events were reported. Conclusions: Although the intervention did not significantly reduce anxiety disorders at 12 months, improvements across all other assessed outcomes indicate this approach brings wider immediate benefits and reduces known risks for future anxiety disorders. Future research needs to consider longer‐term preventative effects.


  • Open Access

    Clinical effectiveness and cost-effectiveness of the rehabilitation enablement in chronic heart failure facilitated self-care rehabilitation intervention for people with heart failure with preserved ejection fraction and their caregivers: rationale and protocol for a multicentre randomised controlled trial – REACH-HFpEF trial

    by Rod S Taylor, Emma Burrell, Claire O’hAre, Elizabeth A Thomson, Anna Placzek, Jessica C Bollen, John G F Cleland, Aynsley Cowie, Hasnain M Dalal, Christi Deaton, et al.

    Introduction Heart failure with preserved ejection fraction (HFpEF) is common and causes functional limitation, poor health-related quality of life (HRQoL) and impairs prognosis. Exercise-based cardiac rehabilitation is a promising intervention for HFpEF, but there is currently insufficient evidence to support its routine use. This trial will assess the clinical and cost-effectiveness of a 12-week health professional-facilitated, home-based rehabilitation intervention (REACH-HF), in people with HFpEF, for participants and their caregivers. Methods and analysis REACH-HFpEF is a parallel two group multicentre randomised controlled trial with 1:1 individual allocation to the REACH-HF intervention plus usual care (intervention group) or usual care alone (control group) with a target sample size of 372 participants with HFpEF and their caregivers recruited from secondary care centres in United Kingdom. Outcome assessment and statistical analysis will be performed blinded; outcomes will be assessed at baseline and 4-month and 12-month follow-up. The primary outcome measure will be patients’ disease-specific HRQoL, measured using the Minnesota Living with Heart Failure questionnaire, at 12 months. Secondary outcomes include patient's exercise capacity, psychological well-being, level of physical activity, generic HRQoL, self-management, frailty, blood biomarkers, mortality, hospitalisations, and serious adverse events, and caregiver's HRQoL and burden. A process evaluation and substudy will assess the fidelity of intervention delivery and adherence to the home-based exercise regime and explore potential mediators and moderators of changes in HRQoL with the intervention. Qualitative studies will describe facilitators’ experiences of delivery of the intervention. A cost-effectiveness analysis (CEA) of the REACH-HF intervention in participants with HFpEF will estimate incremental cost per quality-adjusted life year at 12 months. The CEA will be conducted from a UK NHS and Personal Social Services perspective and a wider societal perspective. The adequacy of trial recruitment in an initial 6-month internal pilot period will also be checked. Ethics and dissemination The study is approved by the West of Scotland Research Ethics Committee (ref 21/WS/0085). Results will be disseminated via peer-reviewed journal publication and conference presentations to researchers, service users and policymakers. Trial registration number ISRCTN47894539.


  • Project publication: Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial

    by Lucy C Chappell, Peter Brocklehurst, Marcus Green, Pollyanna Hardy, Rachael Hunter, Alice Beardmore-Gray, Ursula Bowler, Anna Brockbank, Virginia Chiocchia, Alice Cox, et al.

  • Prognostic indicators of severe disease in late preterm pre-eclampsia to guide decision making on timing of delivery: the PEACOCK study

    by Lucy C Chappell, Peter Brocklehurst, Marcus Green, Pollyanna Hardy, Rachael Hunter, Alice Beardmore-Gray, Ursula Bowler, Anna Brockbank, Virginia Chiocchia, Alice Cox, et al.

    Objective: To assess the diagnostic performance of angiogenic biomarkers in determining need for delivery in seven days in women with late preterm preeclampsia. Study design: In a prospective observational cohort study in 36 maternity units across England and Wales, we studied the diagnostic accuracy of placental growth factor (PlGF) and sFlt-1 in determining the risk of complications requiring delivery in late preterm (34+0 to 36+6 weeks' gestation) preeclampsia. Angiogenic biomarkers were measured using the Quidel (PlGF) and Roche (sFlt-1 : PlGF ratio) assays. Additional clinical data was obtained for use within the established ʻPrediction of complications in early-onset pre-eclampsiaʼ (PREP)-S prognostic model. Biomarkers were assessed using standard methods (sensitivity, specificity, Receiver Operator Curve areas). Estimated probability of early delivery from PREP-S was compared to actual event rates. Main outcome measures: Clinically indicated need for delivery for pre-eclampsia within seven days. Results: PlGF (Quidel) testing had high sensitivity (97.9%) for delivery within seven days, but negative predictive value was only 71.4%, with low specificity (8.4%), with similar results from sFlt-1/PlGF assay. The area under the curve for PlGF was 0.60 (SE 0.03), and 0.65 (0.03), and 0.64 (0.03) for PREP-S in combination with PlGF, and sFlt-1 : PlGF, respectively. Conclusions: Angiogenic biomarkers do not add to clinical assessment to help determine need for delivery for women with late preterm pre-eclampsia. Existing models developed in women with early-onset pre-eclampsia to predict complications cannot be used to predict clinically indicated need for delivery in women with late preterm pre-eclampsia.

  • Project publication: Two-year follow-up of infant and maternal outcomes after planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial

    by Lucy C Chappell, Peter Brocklehurst, Marcus Green, Pollyanna Hardy, Rachael Hunter, Alice Beardmore-Gray, Ursula Bowler, Anna Brockbank, Virginia Chiocchia, Alice Cox, et al.

    Objective: We evaluated the best time to initiate delivery in late preterm pre-eclampsia in order to optimise long-term infant and maternal outcomes. Design: Parallel-group, non-masked, randomised controlled trial. Setting: 46 UK maternity units. Population: Women with pre-eclampsia between 34+0 and 36+6 weeks’ gestation, without severe disease, were randomised to planned delivery or expectant management. Primary long-term outcome: Infant neurodevelopmental outcome at 2 years of age, using the PARCA-R (Parent Report of Children’s Abilities-Revised) composite score. Results: Between 29 September 2014 and 10 December 2018, 901 women were enrolled in the trial, with 450 allocated to planned delivery and 451 to expectant management. At 2-year follow-up, the intention-to-treat analysis population included 276 women (290 infants) allocated to planned delivery and 251 women (256 infants) to expectant management. The mean composite standardised PARCA-R scores were 89.5 [standard deviation (SD) 18.2] in the planned delivery group and 91.9 (SD 18.4) in the expectant management group, with an adjusted mean difference of −2.4 (95% CI −5.4 to 0.5) points. Conclusion: In infants of women with late preterm pre-eclampsia, average neurodevelopmental assessment at 2 years lies within the normal range, regardless of whether planned delivery or expectant management is pursued. Because of lower than anticipated follow-up, there was limited power to demonstrate these scores were not different, but the small between-group difference in PARCA-R scores is unlikely to be clinically important.

  • Cost-utility analysis of planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX)

    by Lucy C Chappell, Peter Brocklehurst, Marcus Green, Pollyanna Hardy, Rachael Hunter, Alice Beardmore-Gray, Ursula Bowler, Anna Brockbank, Virginia Chiocchia, Alice Cox, et al.

    Aim: There is currently limited evidence on the costs associated with late preterm pre-eclampsia beyond antenatal care and post-natal discharge from hospital. The aim of this analysis is to evaluate the 24-month cost-utility of planned delivery for women with late preterm pre-eclampsia at 34+0 and 36+6 weeks’ gestation compared to expectant management from an English National Health Service perspective using participant-level data from the PHOENIX trial. Methods: Women between 34+0 and 36+6 weeks' gestation in 46 maternity units in England and Wales were individually randomised to planned delivery or expectant management. Resource use was collected from hospital records between randomisation and primary hospital discharge following birth. Women were followed up at 6 months and 24 months following birth and self-reported resource use for themselves and their infant(s) covering the previous 6 months. Women completed the EQ-5D-5L at randomisation and follow-up. Results: A total of 450 women were randomised to planned delivery, 451 to expectant management: 187 and 170 women, respectively, had complete data at 24 months. Planned delivery resulted in a significantly lower mean cost per woman and infant(s) over 24 months [−£2711, 95% confidence interval (CI) −4840 to −637], with a mean incremental difference in QALYs of 0.019 (95% CI −0.039 to 0.063). Short-term and 24-month infant costs were not significantly different between the intervention arms. There is a 99% probability that planned delivery is cost-effective at all thresholds below £37,000 per QALY gained. Conclusion: There is a high probability that planned delivery is cost-effective compared to expectant management. These results need to be considered alongside clinical outcomes and in the wider context of maternity care. Trial registration: ISRCTN registry ISRCTN01879376. Registered 25 November 2013.

  • Planned delivery for pre-eclampsia between 34 and 37 weeks of gestation: the PHOENIX RCT

    by Lucy C Chappell, Peter Brocklehurst, Marcus Green, Pollyanna Hardy, Rachael Hunter, Alice Beardmore-Gray, Ursula Bowler, Anna Brockbank, Virginia Chiocchia, Alice Cox, et al.

    Background: In women with late preterm pre-eclampsia, the optimal time to initiate delivery is unclear because limitation of maternal disease progression needs to be balanced against infant complications. The aim of this trial was to determine whether planned earlier initiation of delivery reduces maternal adverse outcomes without substantial worsening of neonatal or infant outcomes, compared with expectant management (usual care) in women with late preterm pre-eclampsia. Methods: In this parallel-group, non-masked, multicentre, randomised controlled trial done in 46 maternity units across England and Wales, we compared planned delivery versus expectant management (usual care) with individual randomisation in women with late preterm pre-eclampsia from 34 to p = 0.0034]. The results from the per-protocol analysis were similar. There were 9 serious adverse events in the planned delivery group and 12 in the expectant management group. Interpretation: There is strong evidence to suggest that planned delivery reduces maternal morbidity and severe hypertension compared with expectant management, with more neonatal unit admissions related to prematurity but no indicators of greater neonatal morbidity. This trade-off should be discussed with women with late preterm pre-eclampsia to allow shared decision making on timing of delivery. Funding: National Institute for Health and Care Research Health Technology Assessment programme.


  • Open Access

    Two‐year follow‐up of infant and maternal outcomes after planned early delivery or expectant management for late preterm pre‐eclampsia (PHOENIX): A randomised controlled trial

    by Alice Beardmore‐Gray, Melanie Greenland, Louise Linsell, Edmund Juszczak, Pollyanna Hardy, Anna Placzek, Rachael Hunter, Jenie Sparkes, Marcus Green, Andrew Shennan, et al.

    Objective: We evaluated the best time to initiate delivery in late preterm pre‐eclampsia in order to optimise long‐term infant and maternal outcomes.Design: Parallel‐group, non‐masked, randomised controlled trial.Setting: Forty‐six maternity units in the UK.Population: Women with pre‐eclampsia between 34+0 and 36+6 weeks of gestation, without severe disease, were randomised to planned delivery or expectant management.Main outcome measures: Infant neurodevelopmental outcome at 2 years of age, using the Parent Report of Children’s Abilities – Revised (PARCA‐R) composite score.Results: Between 29 September 2014 and 10 December 2018, 901 women were enrolled in the trial, with 450 women allocated to planned delivery and 451 women allocated to expectant management. At the 2‐year follow‐up, the intention‐to‐treat analysis population included 276 women (290 infants) allocated to planned delivery and 251 women (256 infants) allocated to expectant management. The mean composite standardised PARCA‐R scores were 89.5 (SD 18.2) in the planned delivery group and 91.9 (SD 18.4) in the expectant management group, with an adjusted mean difference of −2.4 points (95% CI −5.4 to 0.5 points).Conclusions: In infants of women with late preterm pre‐eclampsia, the average neurodevelopmental assessment at 2 years lies within the normal range, regardless of whether planned delivery or expectant management was pursued. With the lower than anticipated follow‐up rate there was limited power to demonstrate that these scores did not differ, but the small between‐group difference in PARCA‐R scores is unlikely to be clinically important.


  • Planned delivery to improve postpartum cardiac function in women with preterm pre-eclampsia: the PHOEBE mechanisms of action study within the PHOENIX RCT

    by Fergus P McCarthy, Jamie O’dRiscoll, Paul Seed, Anna Brockbank, Alice Cox, Carolyn Gill, Marcus Green, Mike Marber, Lucilla Poston, Anna Placzek, et al.

    Background: Women whose pregnancies are affected by hypertensive disorders of pregnancy, in particular preterm pre-eclampsia, are at increased risk of long-term cardiovascular morbidity and mortality. Objectives: To investigate the hypothesis that prolongation of a pregnancy affected by preterm pre-eclampsia managed by expectant management compared with planned early delivery would result in worse cardiovascular function 6 months postpartum. Design: A randomised controlled trial. Setting: 28 maternity hospitals in England and Wales. Participants: Women who were eligible for the Pre-eclampsia in HOspital: Early iNductIon or eXpectant management (PHOENIX) study were approached and recruited for the PHOEBE study. The PHOENIX (Pre-eclampsia in HOspital: Early iNductIon or eXpectant management) study was a parallel-group, non-masked, multicentre, randomised controlled trial that was carried out in 46 maternity units across England and Wales. This study compared planned early delivery with expectant management (usual care) with individual randomisation in women with late preterm pre-eclampsia who were 34 weeks’ gestation to less than 37 weeks’ gestation and having a singleton or dichorionic diamniotic twin pregnancy. Interventions: Postpartum follow-up included medical history, blood pressure assessment and echocardiography. All women had blood sampling performed on at least two time points from recruitment to the 6-month follow-up for assessment of cardiac necrosis markers. Main outcome measures: Primary outcome was a composite of systolic and/or diastolic dysfunction (originally by 2009 guidelines then updated by 2016 guidelines, with an amended definition of diastolic dysfunction). Analyses were by intention to treat, together with a per-protocol analysis for the primary and secondary outcomes. Results: Between 27 April 2016 and 30 November 2018, 623 women were found to be eligible, of whom 420 (67%) were recruited across 28 maternity units in England and Wales. A total of 133 women were allocated to planned delivery, 137 women were allocated to expectant management and a further 150 received non-randomised expectant management within usual care. The mean time from enrolment to delivery was 2.5 (standard deviation 1.9) days in the planned delivery group compared with 6.8 (standard deviation 5.3) days in the expectant management group. There were no differences in the primary outcome between women in the planned delivery group and those in the expectant management group using either the 2009 (risk ratio 1.06, 95% confidence interval 0.80 to 1.40) or the 2016 definition (risk ratio 0.78, 95% confidence interval 0.33 to 1.86). Overall, 10% (31/321) of women had a left ventricular ejection fraction < 55% and 71% of the cohort remained hypertensive at 6 months postpartum. No differences were observed between groups in cardiorespiratory outcomes prior to discharge from hospital or in systolic or diastolic blood pressure measurements. Variables associated with the primary outcome (2009 definition) at 6 months postpartum were maternal body mass index (adjusted odds ratio 1.33 per 5 kg/m2, 95% confidence interval 1.12 to 1.59 per 5 kg/m2) and maternal age (adjusted odds ratio 2.16, 95% confidence interval 1.44 to 3.22 per 10 years). Limitations include changing definitions regarding systolic and/or diastolic dysfunction. Conclusions: Preterm pre-eclampsia results in persistence of hypertension in the majority of women with late preterm pre-eclampsia at 6 months postpartum and systolic dysfunction in 10%. Pre-eclampsia should not be considered a self-limiting disease of pregnancy alone. Future work: Interventions aimed at reducing cardiovascular dysfunction. Trial registration: Current Controlled Trials ISRCTN01879376. Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. This will be published in full in Efficacy and Mechanism Evaluation; Vol. 8, No. 12. See the NIHR Journals Library website for further project information.